摘要
目的:评价联合西格列汀治疗血糖控制不佳的2型糖尿病患者的有效性及安全性。方法:54例单一口服药治疗(二甲双胍16例,磺脲类38例)的2型糖尿病患者,糖化血红蛋白未达标(HbA1c>6.5%),联合西格列汀100 mg,po qd治疗24周,比较治疗前后血糖控制情况,不良反应及体质量增加情况。结果:治疗后HbA1c较治疗前降低了0.91%,FPG降低了1.3mmol·L-1,PPG降低了3.8 mmol·L-1,差异均有统计学意义(P<0.01)。24周发生低血糖1人次,其他不良反应3例。体质指数与治疗前比差异无统计学意义(P>0.05)。结论:西格列汀联合治疗可明显改善血糖控制,低血糖发生少,不良反应少。
Objective： To assess the efficacy and safety of the combination therapy with sitagliptin in type 2 diabetes with inadequate glycemic control by single drug therapy.Method： Totally 54 patients with type 2 diabetes and inadequate glycemic control by metformin（16 patients）or sulfonylurea（38 patients）（Glycated hemoglobin did not reach the standard,HbA1c6.5%） were orally given sitagliptin 100 mg for 24 weeks.The blood glucose control,adverse reactions and body weight changes were compared before and after the treatment.Result： Sitagliptin showed significant effects on HbA1c（-0.91%）,fasting plasma glucose（-1.3 mmol·L-1） and postprandial plasma glucose（-3.8 mmol·L-1）（P0.01）.The incidence of hypoglycemia was much low,only one case in the whole 24 weeks,two patients had gastrointestinal adverse reactions,and one patient had hepatic dysfunction.No significant body weight changes were observed with sitagliptin（P0.05）.Conclusion： In the 24-week study,the combination therapy with sitagliptin can improve glycemic control in type 2 diabetes with low incidence of hypoglycemia and adverse reactions.
出处
《中国药师》
CAS
2012年第10期1465-1467,共3页
China Pharmacist
关键词
西格列汀
2型糖尿病
联合治疗
Sitagliptin
Type 2 diabetes
Combination therapy
